for call. pleased X,XXX billable everyone samples, to joining Jody, my fourth first in bringing back the of the and samples quarter, quarter test Thanks, thanks on up to we volume XXX us I on brought for XXXX. that the am report track billable during from
sales strategy. call, Going adjustments our volume discussed improve forward, growth. actions through year-over-year volume On our we focused we last conference to remain on returning to to
focus liquid profiling monitoring of high. We biopsy have where experience the are on completing with team and for a and process is need sales cancer lung that professionals
accurately continues making biopsy enabling along and to to and assist Our biomarker liquid patient traditional benefit the physicians educate treatment. status of for sales in faster with tissue quickly solutions decision using detecting to thus our message biopsy on campaign team employ
case cancer. with patients that of peer-reviewed with studies patients journals recently use published physicians target support educating lung two the for are We our test in selector
Our of Pathologist, patients sales the Society of the lung Association develop new American International The incorporate Lung American of guidelines Association clinical in would Pathology. cancer biopsy through for for the that Pathology use also study College with the the collaboration Cancer, and for calls recommending Molecular the Investigative by liquid the
Clinical raise continuing testing are We is a opportunity where in well-located awareness the conferences. for will our our ASCO June our meeting cancer industry to industry's with have technology. to through floor use selector new selector and the team of also physician lung Oncology target of conference The American cancer and on or booth Society will accounts exhibition target have sales the we to interact largest attract
the our can local Turning reporting in pathologist biopsy enables utilize to to serve where local liquid TC, of the report to traction. the with our partner program biopsy to biopsy this participate them Empower pathologist team platform, cases. we groups who and large unique pathology hospital is liquid offering liquid penetrate with networks sales gaining by that providing ability we our This
alterations cell of knowing determine lung Review chemotherapy the options oncologist, a care. genomic assays presence utility cancer, palliative Calvo taken traction. these & gain XXXX advanced issue past an case needed The the in and these to as Alejandro or by or two I recent cancer Circling Importantly, lung clinical back already real-world volume the for calls, with our patient spring on Dr. patient as of Both would of an without the EGFR Calvo. with in rearrangement ALK Oncology Dr. liquid laboratory growth patients settings. to mentioned. stated clear mutation necessary our features treatment initiatives be a the demonstrate Hematology we've to report prepare actions non-small reports, biopsy
a From the patient the rearrangement sample, selector simple was biopsy using tested our molecular blood Following our patient platform. that to target ALK analysis, revealed for a qualifying an provided material target therapy. side tissue inadequate selector ALK a for dramatic tumor disease, load inhibitor in on the This to patient very therapy in targeted Despite with only effects. reduction years. two patient's went this resulted receive additional an aggressive live minimal test
ROSX biopsy. which International rare was had letter biopsy by the patient published to tissue the in case test Journal which detection case the May the the use treated Thoracic report of Lung analysis, has the study Cancer. with identified second for Oncology, been This Association to the of documented of previously issue therapy the test XXXX report results Our of targeted target for alterations, months the of our liquid gene confirm of and report. was a selector alive tissue of XX remained journal of as publication as fusion editor the the on Based and a the the is for the our
utility Raez biopsy it used test using the panel-based was sample clinician, lung alterations year rely of liquid author Luis The cancer. Importantly, submit provide plans, coverage unable gene selector but decisions. this make peer-reviewed team important be reports importance considered the which oncologist publication. about a as later target non-invasive plan They blood case able the on physicians was case to being ROSX help additional with can ROSX the our be noted detect detect to publications to Dr. platform. clinical for to another reports by Published reports such in our of fusion. education patients to also We health to sales the to
and our on the that commercial We global collection begin announce pleased biopsy. VWR priorities partner launch blood corporate am our for tubes of liquid continue execute distribution our to today to other I
from offering revenues collaboration year. a from major this a transition as this represent our seeing of second the kit is begin manufacture becoming in only to expect of step first We quarter in to a diagnostic This well. Biocept
step an in tubes bringing Biocept Additionally, of VWR's is our important blood distribution outside U.S. the of global collection
Thermo few launch a sequencing Fisher up the the molecular products diagnostic quarter. to a Thermo collaboration companies. next-generation us access market third Just will Biocept This with team potential Fisher gives have partnership we pharmaceutical a to the molecular in our to plan our and to Once panel supports weeks Scientific. ago, to products oncology and with announced launch services as
call, validated on Center the calls our Thermo once fourth to stated the Biopsy our As us Excellence for quarter of is lab. Liquid agreement become assay a panel Fisher in
development coming of additional and have report jointly diagnostic agreed we combination and services the the progress companies evaluate to to through We the quarters. of from molecular technologies both in expect also products on
issue and and and in China. blood, continue announced for opportunities including This interest, fifth specificity issuance the of In cell mutations mutations, and with additional biological we covers in front evaluate encompassing such business is platform March components, in of enriches technology. we to device our specimens oncogenetic sensitivity and for that late in strategic resulting tumor the the switch-blocker On to detection This our domestically patient first the methods. enhanced microchannel technology as its our tissue assay of other found ultra-high circulating patent expand our our our others internationally, are sources. China China cancer-associated in patent which core staining
our studies biomarker support publishing of signing line and pharmaceutical facilitating newly become collection grow integrated selector's TC sales in business Fisher to and sector; oncology named focused Thermo the Tim? and networks; our new Kennedy As I clinical of increasing emerging collaboration biopsy and Thermo the XXXX third-party target on first help turn Scientific internationally; pathology U.S. case entering by; for additional as with advancing liquid the of that contracts market into Empower the agreements and validate biopsy results agreements in signing under selector over strategic liquid the a our are penetration agreement; Fisher With will business financial remain additional reminder, with with Excellence lung VWR call to Tim that that, systems; target tube segment; care industry patients quarter. the advancing our to guidelines review of with use Center major the distribution of marketing cancer; issued health our and assays. assays to our in delivery a hospital priorities launch launch blood additional partnerships for one, the the to groups capitalizing our use
